Reducing the percentage of individuals with monogenic diabetes who are receiving only insulin at the start of the model has little impact on the incremental costs estimated: even if 10% of individuals with GCK mutations or 10% of individuals with HNF1A or HNF4A mutations are on tablets at the start of the model, slight cost savings are still estimated with the Clinical Prediction Model Testing and Biomarker Testing strategies compared with the No Testing strategy (see figures 5 and 6). This evidence concerns the gene HNF1A and diabetes mellitus.